JP2025503176A5 - - Google Patents
Info
- Publication number
- JP2025503176A5 JP2025503176A5 JP2024544412A JP2024544412A JP2025503176A5 JP 2025503176 A5 JP2025503176 A5 JP 2025503176A5 JP 2024544412 A JP2024544412 A JP 2024544412A JP 2024544412 A JP2024544412 A JP 2024544412A JP 2025503176 A5 JP2025503176 A5 JP 2025503176A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263304424P | 2022-01-28 | 2022-01-28 | |
| US63/304,424 | 2022-01-28 | ||
| PCT/EP2023/051979 WO2023144290A1 (en) | 2022-01-28 | 2023-01-27 | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025503176A JP2025503176A (ja) | 2025-01-30 |
| JPWO2023144290A5 JPWO2023144290A5 (https=) | 2026-02-10 |
| JP2025503176A5 true JP2025503176A5 (https=) | 2026-02-10 |
Family
ID=85158800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024544412A Pending JP2025503176A (ja) | 2022-01-28 | 2023-01-27 | びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230241211A1 (https=) |
| EP (1) | EP4469082A1 (https=) |
| JP (1) | JP2025503176A (https=) |
| KR (1) | KR20240135663A (https=) |
| CN (1) | CN118613281A (https=) |
| AU (1) | AU2023214116A1 (https=) |
| CA (1) | CA3243415A1 (https=) |
| IL (1) | IL314344A (https=) |
| MX (1) | MX2024008833A (https=) |
| TW (1) | TW202345895A (https=) |
| WO (1) | WO2023144290A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3176436A1 (en) | 2020-05-08 | 2021-11-11 | Tahamtan Ahmadi | Bispecific antibodies against cd3 and cd20 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| JP4213224B2 (ja) | 1997-05-02 | 2009-01-21 | ジェネンテック，インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
| CN101928344B (zh) | 2002-10-17 | 2014-08-13 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
| US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| JP2012525149A (ja) | 2009-04-27 | 2012-10-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ヘテロ多量体分子を作製するための方法 |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| DK2560993T3 (da) | 2010-04-20 | 2024-10-14 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| US10344050B2 (en) | 2011-10-27 | 2019-07-09 | Genmab A/S | Production of heterodimeric proteins |
| MX373245B (es) | 2013-07-05 | 2020-05-11 | Genmab As | Anticuerpos cd3 humanizados o quiméricos. |
| WO2016007854A1 (en) * | 2014-07-11 | 2016-01-14 | Celgene Corporation | Combination therapy for cancer |
| CN107660214B (zh) | 2015-01-08 | 2022-02-08 | 根马布股份公司 | 针对cd3和cd20的双特异性抗体 |
| BR112020015052A2 (pt) | 2018-02-09 | 2020-12-08 | Genmab A/S | Composição farmacêutica, uso da composição farmacêutica, métodos para tratar câncer em um sujeito, para preparar uma composição farmacêutica e para preparar uma forma de dosagem unitária, forma de dosagem unitária, recipiente, e, kit-de-partes |
| KR20210104713A (ko) * | 2018-11-16 | 2021-08-25 | 주노 쎄러퓨티크스 인코퍼레이티드 | Ｂ 세포 악성 종양 치료를 위한 조작된 ｔ 세포 투약 방법 |
| EP4210742A1 (en) * | 2020-09-10 | 2023-07-19 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
-
2023
- 2023-01-27 CA CA3243415A patent/CA3243415A1/en active Pending
- 2023-01-27 US US18/160,386 patent/US20230241211A1/en active Pending
- 2023-01-27 MX MX2024008833A patent/MX2024008833A/es unknown
- 2023-01-27 US US18/833,261 patent/US20250115665A1/en active Pending
- 2023-01-27 KR KR1020247028130A patent/KR20240135663A/ko active Pending
- 2023-01-27 WO PCT/EP2023/051979 patent/WO2023144290A1/en not_active Ceased
- 2023-01-27 EP EP23702966.5A patent/EP4469082A1/en active Pending
- 2023-01-27 JP JP2024544412A patent/JP2025503176A/ja active Pending
- 2023-01-27 IL IL314344A patent/IL314344A/en unknown
- 2023-01-27 CN CN202380018858.8A patent/CN118613281A/zh active Pending
- 2023-01-27 AU AU2023214116A patent/AU2023214116A1/en active Pending
- 2023-01-30 TW TW112103163A patent/TW202345895A/zh unknown